Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease.

On the contrary, one in three patients (33%) with grade 5 CKD required treatment discontinuation and HD initiation due to immune-related pneumonitis and colitis. Among all patients, three patients (43%) experienced grade 3 or more immune-related adverse events (irAEs) and required corticosteroid administration. Abbreviations CKD chronic kidney disease HD hemodialysis ICI immune checkpoint inhibitor irAE immune-related adverse events RCC renal cell carcinoma RRT renal replacement therapies Renal cell carcinoma (RCC) is correlated with renal impairment. [Extracted from the article]